Eli Lilly (NYSE: LLY) presented financials this morning, showing that fourth-quarter 2016 revenue rose 7.2% to $5.76 billion, beating analysts' average estimate of $5.55 billion, helped by the strong performance of its diabetes drug franchise.
The US pharma major’s reported net income rocketed 61% to $771.8 million, or $0.73 per share. However, Lilly's non-generally accepted accounting principles (GAAP) earnings per share at $0.95 (up 22%) were below the $0.99 per share average analysts' expectations of nine analysts surveyed by Zacks Investment Research. on average.
Lilly’s shares were up 2.5% at $76.58 by late morning trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze